Aptamer Group Plc ( ($GB:APTA) ) has provided an update. Aptamer Group has secured a significant new contract with a top five pharmaceutical ...

Optimer binders against three therapeutic targets to support drug validation and potential clinical trial applications ...

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new ...

Aptamer Group plc, the developer of novel Optimer ® binders to enable innovation in the life sciences industry, today announces the signing of a new development contract with a rare disease ...

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, presented new data on its Optimer therapeutic delivery vehicle for ...

Researchers have figured out a way to make an RNA biosensor that fluoresces when it encounters small inorganic metabolites—not by engineering the RNA but by adjusting its fluorogenic ligand molecule.

The 2012 landmark Science paper demonstrating the use of CRISPR-Cas9 as a gene-editing tool catapulted gene-editing technologies to new levels. Yet, that breakthrough also highlighted precision and ...